Regeneron to Acquire 23andMe for $256M

Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy.
More Videos
Watch Cheddar News
Business, tech, innovation — Cheddar covers all of it with exclusive shows and thought-provoking interviews.
Load More